Cargando…
The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
BACKGROUND: Schizophrenia is a chronic disease that requires long-term management with antipsychotics; however, an important barrier to the success of long-term treatment is drug noncompliance, which increases the risk of recurrence and hospitalization. Second-generation long-acting injectable antip...
Autores principales: | Suzuki, Hidenobu, Hibino, Hiroyuki, Inoue, Yuichi, Matsumoto, Hideo, Mikami, Katsunaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448866/ https://www.ncbi.nlm.nih.gov/pubmed/28596830 http://dx.doi.org/10.1177/2050313X17710594 |
Ejemplares similares
-
One patient with schizophrenia showed reduced drug-induced extrapyramidal symptoms as a result of an alternative regimen of treatment with paliperidone 3 and 6 mg every other day
por: Suzuki, Hidenobu, et al.
Publicado: (2017) -
Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021) -
Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Liang, Chih-Sung, et al.
Publicado: (2021) -
Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014) -
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)